Wet AMD Market Snapshot: A High-Growth Market Poised For Change

The US treatment market for wet age-related macular degeneration has been solidly established for a decade, dominated by two powerhouse anti-vascular endothelial growth factor (VEGF) brands: Regeneron Pharmaceuticals, Inc.'s Eylea (aflibercept) and Roche Holding AG's Lucentis (ranibizumab). In the next six months, however, the market is poised for a shakeup with the potential launch of the first biosimilar version of Lucentis in the US and the first bispecific antibody for wet AMD, Roche's faricimab.

Regeneron's top priority is defending its market leadership position in the category with Eylea, the company's top-seller and a high-growth brand even after 10 years on the market